Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio drug development company Curetech Ltd. has obtained US Food and Drug Administration (FDA) approval for a Phase I/II clinical trial for the treatment of liver cancer. Curetech's leading drug candidate, CT-011, is intended to treat hepatocellular carcinoma. [...]
Curetech is meanwhile continuing the Phase II trial of CT-011 for the treatment of blood and colon cancers and the Phase I/II trial for the treatment of chronic hepatitis C.
Lire l'intégralité de l'article » (Source: Globes)
Antiboycott Israel blog: cancer du foie, cancer du colon, hépatite C